Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Atilotrelvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Atilotrelvir is an oral antiviral for COVID-19, developed in China and sold there as 泰中定® (the pack also carries the English name Tazovid). It comes as a combination pack: each box holds atilotrelvir tablets together with low-dose ritonavir tablets, and the two are always swallowed together. A full course lasts just five days.
China's National Medical Products Administration (NMPA) granted it conditional approval in November 2023, through its emergency review route, for adults with:
Because the virus keeps changing, the approval asks the company to keep checking that the medicine still works against the strains in circulation. It is a prescription infection medicine and should only be taken on a doctor's advice.
To multiply inside the body, the coronavirus has to cut its long chain of proteins into working parts, using an enzyme called the 3CL (main) protease. Atilotrelvir blocks that enzyme, so the virus cannot finish copying itself. The small dose of ritonavir does not fight the virus here; it slows the breakdown of atilotrelvir in the liver, so enough of the medicine stays in the blood to work.
The phase 2/3 trial, published in eClinicalMedicine in 2024, enrolled 1,246 adults with mild or moderate COVID-19 at 47 hospitals in China. Most were young, vaccinated and at low risk. Compared with placebo, people taking the combination recovered from all 11 tracked symptoms a little sooner (median 13 vs 15 days). The virus also cleared faster: by day 5 the viral load had dropped by an extra 1.75 log10 copies/mL compared with placebo, and the median time to a negative test was 11 vs 14 days. No one in either group developed severe COVID-19 or died, so the trial could not show whether it prevents serious illness.
Atilotrelvir must never be taken without ritonavir, because on its own the blood level may be too low to work. No dose change is needed for mild or moderate liver impairment, but it should not be used with severe liver impairment. It has not been studied in people with kidney problems.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Drug interactions (most important): ritonavir strongly blocks a liver enzyme called CYP3A, which many common medicines rely on. Taken together, some heart-rhythm, pain, sedative, cholesterol and other medicines can build up to dangerous levels, while certain medicines and herbal remedies can lower atilotrelvir levels and stop it working. The Chinese leaflet lists medicines that must not be combined with it. Always show your doctor a full list of everything you take, including herbal products, before starting.
Overall: in the trial, side effects were reported in 51.9% of people on the combination and 48.9% on placebo. Serious events were rare (0.2% vs 0.3%), none was linked to the medicine, and 0.6% stopped treatment. It has not been tested in children under 18, and data in older adults are limited.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit. Because treatment should begin within 3 days of the first symptoms, please contact us as early as possible.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. NPP also arranges other antiviral medicines that are not sold in India, such as Livtencity.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box is one complete 5-day course: two blister strips, each holding 5 atilotrelvir and 5 ritonavir tablets. The label asks for the pack to be kept sealed at no more than 25°C, so it travels in its original packaging under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid doctor's prescription.
Close to our New Delhi dispatch point, which helps when a five-day course needs to start within days of the first symptoms.
Physicians in Mumbai can send the prescription and test report together so the import can begin straight away.
Patients in Bangalore can have the course delivered to their home or clinic once the documents are checked.
We share the quote and expected delivery time first, so the doctor can decide whether the timing still fits.
Infectious disease specialists in Hyderabad can request the medicine for a named patient, with the medicine list checked for interactions.
For Kolkata and the eastern states, deliveries are planned around the short treatment window.
Patients in Pune can use the same documented import route, with updates at every stage.
The treating doctor can share the prescription and current medicines list to start the request.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
Patients in Rajasthan can receive the pack without travelling, as long as the import is in their name.
We coordinate delivery for patients treated at public and private hospitals across Uttar Pradesh.
Patients across Kerala can have the course delivered to their home or hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
